2017 - CIRTA


This page contains exclusive content for the member of the following sections: TTS, ITA. Log in to view.

10- Intestinal Transplantation

52.21 - Intestinal Transplantation is cost effective in the treatment of complicated intestinal failure

Presenter: Emilio, Canovai, Leuven, Belgium
Authors: Emilio Canovai, Laurens Ceulemans, Guido Peers, Lutgard Le Pourcq, Marleen Pijpops, Marguerite Stas, Ilse Hoffman, Gert De Hertogh, Martin Hiele, Tim Vanuytsel, Jacques Pirenne

Intestinal Transplantation is cost effective in the treatment of complicated intestinal failure

Emilio Canovai1, Laurens Ceulemans1, Guido Peers2, Lutgard Le Pourcq3, Marleen Pijpops3, Marguerite Stas4, Ilse Hoffman5, Gert De Hertogh1, Martin Hiele1, Tim Vanuytsel1, Jacques Pirenne1.

1Leuven Intestinal Failure and Transplantation Center (LIFT), University Hospitals Leuven, Leuven, Belgium; 2Financial Department, University Hospitals Leuven, Leuven, Belgium; 3Pharmacy Department, University Hospitals Leuven, Leuven, Belgium; 4Oncological Surgery, University Hospitals Leuven, Leuven, Belgium; 5Pediatric Department, University Hospitals Leuven, Leuven, Belgium

Introduction: When life-threatening complications occur due to home parenteral nutrition (HPN), intestinal transplantation (ITx) is indicated. ITx is the most expensive solid organ transplant but the true cost effectiveness is unknown.

Aim: To compare the costs of complicated HPN before ITx to the costs after ITx at our institution.

Methods: We performed a retrospective analysis of our cohort of ITx patients, transplanted between 1/1/2000 and 31/12/2015. Total costs analyzed included all costs for surgery, admissions, diagnostics, treatments, outpatient clinics and medication. For those patients followed at our center pre-ITx, the costs before ITx, including the HPN care were included up to 2 years before surgery. All costs for pre-transplant screening were excluded from the pre-transplant data.

Results: 16 patients (12 adults (7 females, mean age 43 years (23-57)) and 4 children (1 female, mean age 8 years (range: 3-17))), were included in this study. 15 patients underwent ITx while 1 patient was listed for ITx at time of analysis. 8 patients were followed at our center pre-ITx and financial data were therefore available. The causes of intestinal failure for the adults were short bowel syndrome (SBS) (67%), diffuse portomesenteric thrombosis (25%) and chronic intestinal pseudo-obstruction (8%). 2 children had SBS after volvulus and 2 children had congenital mucosal diseases. All patients were listed for ITx due to severe complications from HPN or the underlying disease. 7 patients underwent isolated ITx, 5 had a combined Liver-ITx and 3 underwent multivisceral transplantation. The 5-year patient survival was 86.7%. The median costs in year -2 (day 720 – 366 pre-ITx) was € 90 891 (60 682- 342 299) and year – 1 (day 365- 1 pre-ITx) was € 134 006 (83 854 - € 275 712). After ITx, the costs of the first year were € 185 662 (122 483 - 571 301). In year 2, there was a 76% reduction in overall costs to € 44 893 (3 905-293 985) due to a reduction of hospitalizations. In year 1, the patients were hospitalized for a median of 145 days (78-365) while in year 2, this had dropped to 37 days (0-319). In adult patients, the costs drop much faster while remaining quite high until year 3 in children.

Conclusion: Intestinal transplantation, while being an expensive procedure, was cost effective in adults by the second year. In children, ITx was cost effective from the third year onward, because of more complicated treatment of underlying congenital disease.


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada